Thomas E Keene

Title: Thomas E. Keene: Innovator in Baclofen Formulations

Introduction

Thomas E. Keene, an accomplished inventor based in Golden Valley, Minnesota, has made significant contributions to the field of pharmaceutical formulations. With a total of six patents to his name, Keene has focused his innovative efforts primarily on baclofen, a medication commonly used to treat spasticity and other neurological conditions.

Latest Patents

Keene's latest patent involves the development of baclofen formulations and methods for creating sterilized solutions. This invention details a method of preparing baclofen solutions by adjusting the pH to below a desired level and then steam sterilizing these solutions. As a result, the solutions attain the desired pH while potentially minimizing concentrations of 4-CPP. Notably, Keene's injectable baclofen solutions exceed 2 mg/mL, incorporating between 5 mM and 25 mM of phosphate or sulfate species, with an ionic strength comparable to that of 1.5 M NaCl. His formulations are intended for treating a variety of conditions, including spasticity, brain injury, cerebral palsy, spinal cord injury, cervical injury, multiple sclerosis, thoracic injury, and withdrawal symptoms.

Career Highlights

Over the course of his career, Thomas E. Keene has worked with Saol International Limited, where he honed his expertise in pharmaceutical development. His background in this company has been instrumental in shaping his innovative approach toward improving baclofen formulations.

Collaborations

Throughout his career, Keene has collaborated with notable professionals like Michael C. Schmitz and Corinne Dominguez. These partnerships have allowed him to share knowledge and contribute to advancing research and innovation in the treatment of neurological conditions.

Conclusion

Thomas E. Keene is a distinguished inventor whose work on baclofen formulations has the potential to improve patient care in neurological treatment. His patents not only reflect his significant contributions to the field but also his ongoing commitment to innovation in the pharmaceutical industry.